ChemoCentryx to Present at Two Upcoming Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Stifel Starts ChemoCentryx (CCXI) at Buy
March 1, 2021 4:05 PM ESTStifel analyst Dae Gon Ha initiates coverage on ChemoCentryx (NASDAQ: CCXI) with a Buy rating and a price target of $93.00.
The analyst comments "We are positive on this story primarily because of avacopan's opportunity in ANCA-associated vasculitis (AAV). CCXI is at the... More
